To characterize the role of NANOG in immune-refractory features of the TME in an ICB therapy–refractory tumor model, we first assessed the expression of NANOG in CT26 cells at different rounds of immune selection (P0 to P3) and found a stepwise increase in NANOG expression from P0 to P3 (Figure 3A). The gene discussed is NANOG; the disease is neoplasm.